Progressione centri attivati vs pz. trattati. Time delay (median min) Italy All centres Onset to treating hospital/door time 68.075.0 Door to imaging.

Slides:



Advertisements
Similar presentations
3/28/2017© 2009, American Heart Association. All rights reserved.
Advertisements

UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.
Atrial Fibrillation Service
Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic.
Accomplishments in Stroke Care
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
DISCLOSURE INFORMATION (relative only): Eric D. Peterson, PI of the AHA GWTG Data Analysis Center; Lee H. Schwamm, Chair of the AHA National Steering Committee.
Thrombolysis for stroke in older people.
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
G.N. Dalekos3, M. Elisaf2, A.I. Hatzitolios1
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.
EM TREATMENT OF ACUTE STROKE Progress, Problems, Politics William G. Barsan, M.D. University of Michigan.
Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Series 1 of Many- Coding Fracture in ICD-9 VS ICD-10 © Copyright Acucare Health Strategies, Inc. All Rights Reserved.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Edward P. Sloan, MD, MPH FERNE/EMA Session: Treating Ischemic Stroke Patients Using a 3 to 4.5 Hour tPA Window.
Randomized Evaluation of Long- term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke.
Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
European Stroke intervention Guidelines ESMINT/ESO/ESNR/EAN WLNC 2015
Kevin Agostino NOSM Medical Student Dr. Saleem Malik Associate Professor NOSM.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
UDATE ON REVASCAT: (Randomized Trial Of Revascularization With Solitaire FR® Device Versus Best Medical Therapy In The Treatment Of Acute Stroke Due To.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
S afe I mplementation of T hrombolysis in S troke Slide presentation adapted from
RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.
Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.
Update in ESC: Dabigatran among OAC
Simple CBF grading based on MR perfusion to anticipate long-term clinical outcome in severe stroke patients due to the carotid artery occlusion Mori T,
Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
SITS-MOST main outcome results *Corresponding author: Prof. Nils Wahlgren SITS International Coordination Office Karolinska Stroke Research Department.
What is the outcome of Door-to-needle Time within 60minutes for acute ischemic stroke patients treat with t-PA? Chi-Ching Chen 1, Hui-Fen Huang 1, Yu-Ling.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,
Long-Term Clinical Outcome After Emergency MR-based Reperfusion Therapy for Acute Basilar Artery Occlusion Department of Stroke Treatment, Shonan Kamakura.
Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
“Door to Needle (DTN) Time in Stroke Thrombolysis” Audit Care of the Elderly Department Dr Nikoletta Petrou, Foundation Year 1 Doctor Dr Prasanna Aghoram,
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
Outcomes of thrombolysis treatment in patients with dementia and acute ischemic stroke A longitudinal cohort study from SveDem and Riksstroke, Swedish.
History Of Atrial Fibrillation In A First-Degree Relative
From ESH 2016 | POS 4C: A. Power, MD
– р<0.05 between baseline
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Atrial Fibrillation in a CLL Patient Treated with Ibrutinib
When Not to Intervene in Acute Stroke or
Setareh Omran, MD Vascular Neurology Fellow
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Extended Window Thrombectomy
Baseline Data Proper Re-identification
Three outcome measures from the NINDS tPA trial
OPN is elevated in patients with symptomatic AS
A: Probability of SICH by baseline glucose level.
Presentation transcript:

Progressione centri attivati vs pz. trattati

Time delay (median min) Italy All centres Onset to treating hospital/door time Door to imaging study time Door to treatment/needle time Onset to treatment/needle time Time logistics

VariablesItalyAll centres Age6970 Male56%54% Female44%46% NIHSS Median NIHSS 0-732%34% NIHSS %33% NIHSS >1534%33% Current smoker17%16% Previous smoker14%11% Atrial fibrillation18%21% Congestive heart failiure7%8% Systolic Diastolic Demographic and baseline data

Clinical outcome at 3 months mRS 0-2Recovered patients Proportion recovered Lower Confidenc e Limit Upper Confidence Limit Italy971/159461,358,963,7 All centers3033/528658,35759,7 mRS 0-1 Italy781/159449,346,951,8 All centers2262/528643,542,244,9 MortalityDead within 3 months Proportion Dead Lower Confidenc e Limit Upper Confidence Limit Italy174/169410,38,911,8 All centers760/611012,411,613,3

Symptomatic intra-cranial hemorrhage SICH definition SICH patients Proportion SICH Lower Confidence Limit Upper Confidence Limit SITS-MOST Italy36/18961,91,42,6 All centers90/61231,51,21,8 ECASS Italy74/182843,25,1 All centers263/524254,55,6 NINDS Italy123/18286,75,78 All centers367/524276,37,7

Clinical outcome at 3-months (bNIHSS≥10; median 16) mRS 0-2N° of patients ProportionLower Confidenc e Limit Upper Confidenc e Limit Italy335/83440,537,243,8 All centers1055/276238,83740,6 mRS 0-1 Italy233/83428,125,231,3 All centers713/276226,224,627,9 MortalityDead within 3 months Proportion Dead Lower Confidenc e Limit Upper Confidenc e Limit Italy149/90716,414,219 All centers622/329018,917,620,3

Quanti pazienti dovremmo trattare? ~50% non trattabili ≤ 4.5 h 50% ~ ~ ≤ 3 h 30% ≤ 4.5 h 50% ~ ~ ~ ~ Range ~ – pz./anno ≤ 3 h 30% ~ Trattabili con tPA per RCP ~ 25% ~ Nuovi casi Totale Recidive Incidenza Ictus ischemico in Italia 30% / = 14.5%